合并症指数评估用于预测非小细胞肺癌立体定向体部放疗后临床结局
研究纳入2008年11月至2015年1月单中心196例医学上不可手术的早期非小细胞肺癌患者,接受立体定向体部放疗,用年龄校正Charlson合并症指数(aCCI)评估合并症与年龄的预后影响。中位总生存15.0个月(95%CI 11.9-18.1),aCCI≥7较aCCI≤6与死亡风险升高相关(HR 1.79,95%CI 1.02-2.80,p=0.04),aCCI≥9与非癌性死亡相关(HR 3.12,95%CI 1.22-8.33,p=0.02)。作者推荐对所有接受SBRT的肺癌患者使用aCCI进行年龄和合并症指数化评估。
要点
- aCCI≥7较aCCI≤6与死亡风险升高相关(HR 1.79,95%CI 1.02-2.80,p=0.04)。
- aCCI≥9与非癌性死亡相关(HR 3.12,95%CI 1.22-8.33,p=0.02)。
- aCCI≥7较aCCI≤6与癌特异性死亡风险升高相关(HR 9.26,95%CI 4.83-24.39,p<0.001)。
核心结论
- 年龄校正Charlson合并症指数(aCCI)可评估医学上不可手术早期非小细胞肺癌SBRT患者的年龄与合并症对生存的影响。
- 作者推荐对所有接受SBRT的肺癌患者使用aCCI进行年龄和合并症指数化评估。
研究设计与样本
- 单中心研究,2008年11月至2015年1月连续纳入196例医学上不可手术的非小细胞肺癌患者,接受立体定向体部放疗。
- 处方等中心剂量:中央型肺癌为60.0 Gy分6次,周围型肺癌为56.25 Gy分3次。
- 回顾性根据门诊病历及医院信息系统采集基线合并症,对每例患者进行aCCI评分,并按结局、毒性及aCCI各单项和临床参数行单因素和多因素分析。
主要发现
- 中位总生存(OS)为15.0个月(95%CI 11.9-18.1),中位癌特异性生存(CSS)未达到。
- aCCI≥7较aCCI≤6与死亡风险升高相关(HR 1.79,95%CI 1.02-2.80,p=0.04),与癌特异性死亡风险升高相关(HR 9.26,95%CI 4.83-24.39,p<0.001)。
- OS和CSS均与年龄、性别、侧别(左vs右)、肺叶、位置(中央vs周围)、包年、TNM分期或aCCI任何单项无显著关联。
- aCCI≥9较aCCI≤8与非癌性死亡相关(HR 3.12,95%CI 1.22-8.33,p=0.02)。
关键数值与推荐
- aCCI≥7较aCCI≤6与死亡风险升高相关(HR 1.79,95%CI 1.02-2.80,p=0.04)。
- aCCI≥7较aCCI≤6与癌特异性死亡风险升高相关(HR 9.26,95%CI 4.83-24.39,p<0.001)。
- aCCI≥9较aCCI≤8与非癌性死亡相关(HR 3.12,95%CI 1.22-8.33,p=0.02)。
- RP≥2级累积发生率为12.7%(25/196),aCCI与RP无统计学关联。
临床怎么用
- 作者推荐对所有接受SBRT的肺癌患者使用aCCI进行年龄和合并症指数化评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the prognostic impact of comorbidity and age in medically inoperable early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT) using the age-adjusted Charlson Comorbidity Index (aCCI). PATIENTS AND METHODS: Between November 2008 and January 2015, 196 consecutive patients with medically inoperable NSCLC were treated with SBRT at a single institution. The prescribed isocenter dose was either 60.0 Gray (Gy) in six fractions for central lung cancer or 56.25 Gy in three fractions for peripheral lung cancer. Baseline comorbidities were retrospectively retrieved according to available outclinic medical records as well as the hospital information system. The aCCI was scored for each patient and subjected according to outcome and toxicity as well as all of the single items of the aCCI and other clinical parameters using univariate and multivariate analysis. RESULTS: Thirty-one point 6 % (62/196) of patients were deceased, of whom 17.3% (34/196) died due to lung cancer and 14.3% (28/196) due to comorbidities. The median overall survival (OS) was 15.0 months (95% CI [11.9-18.1]), whereas the median cancer-specific survival (CSS) was not reached. An aCCI ≥7 compared with an aCCI ≤6 was significantly associated with an increased risk of death (HR 1.79, 95% CI [1.02-2.80], p = 0.04) and cancer-specific death (HR 9.26, 95% CI [4.83-24.39], p < 0.001), respectively. Neither OS nor CCS were significantly associated with age, sex, side (left vs. right), lobe, localization (central vs. peripheral), packyears, TNM, or any item of the aCCI. Considering the 14.3% (28/196) of deceased patients who died due to comorbidities, aCCI ≥9 was significantly associated with non-cancer-related death (HR 3.12, 95% CI [1.22-8.33], p = 0.02). The observed cumulative rate of radiation pneumonitis (RP) ≥2 was 12.7% (25/196). The aCCI had no statistical association with RP. CONCLUSION: Advanced age and numerous comorbidities characterizing this patient population were successfully assessed using the aCCI in terms of survival. Therefore, we recommend that age and comorbidity be indexed using the aCCI as a simple scoring system for all patients treated with SBRT for lung cancer.
引用
- Dreyer J, Bremer M, Henkenberens C, et al. Comorbidity indexing for prediction of the clinical outcome after stereotactic body radiation therapy in non-small cell lung cancer. Radiat Oncol. 2018. PMID: 30390700. doi:10.1186/s13014-018-1156-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。